PERSPECTA

News from every angle

← Back to headlines

US Regulator Delays Decision on AstraZeneca Cancer Drug

The FDA has extended its review period for an AstraZeneca breast cancer drug after an oncology advisory panel voted against recommending it.

27 May, 08:00 — 27 May, 08:00
PostShare

Sources

Showing 1 of 1 sources
FTVery High11h ago

US regulator delays decision on AstraZeneca cancer drug

Review period extension comes after FDA oncology advisory panel voted against recommending breast cancer drug

Read full article →

Related Stories

Amazon's First Customer Receipt Goes Viral, Bezos and Musk React

just now

Manila Water Prepares for Severe El Niño

just now

Philippines Lawmakers Call for Review of Energy Policies Amid High Costs

just now

DA Plans Cloud Seeding in Negros Occidental to Mitigate Crop Damage

just now